Federal Register #FDA2026N3962

FDA Public Advisory Committee Meeting on 2026-2027 COVID-19 Vaccine Formula

This notice announces a public advisory committee meeting by the Food and Drug Administration (FDA) to discuss the 2026-2027 COVID-19 vaccine formula for use in the United States. - Government Buyer: - Food and Drug Administration (FDA), Department of Health and Human Services - Purpose: - Public advisory committee meeting to discuss and recommend the COVID-19 vaccine formula for 2026-2027 - Open to the public with opportunities for oral and written comments - Establishment of a public docket for comment submissions - Products/Services: - No products or services are being procured or requested - No OEMs or vendors are mentioned - Unique/Notable Requirements: - This is an informational event, not a procurement action - Includes information about a separate NIH advisory council meeting (not related to procurement) - Locations: - FDA headquarters in Rockville, MD - National Institutes of Health, Neuroscience Center in Rockville, MD (for unrelated advisory council meeting)

Description

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee to discuss and make recommendations on the selection of the 2026-2027 formula for COVID-19 vaccines for use in the United States. The meeting will be held virtually on May 28, 2026, from 8:30 a.m. to 4:30 p.m. Eastern Time. FDA is establishing a public docket for comments on this document, which will close on May 27, 2026. The meeting will be open to the public and will include presentations and opportunities for oral and written public comments.

View original listing